Head-to-Head Comparison: Oral Semaglutide vs. Empagliflozin
Nov 23, 2019
Editor: Steve Freed, R.PH., CDE
Author: Jordan Boyd, PharmD. Candidate Florida Agricultural & Mechanical University School of Pharmacy
The first oral glucagon-like peptide receptor agonist recently gained FDA approval, but how does it compare to oral agents already on the market?
With the recent approval of the first oral glucagon-like peptide agonist, Rybelsus (semaglutide), many clinicians are wondering how it stacks up to oral agents that they may already be utilizing in practice. The PIONEER-2 trial conducted by the manufacturer of Rybelsus, Novo Nordisk, evaluated several outcomes associated with its new drug versus Jardiance (empagliflozin) in an open-label, head-to-head comparison....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.